Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Patients With Moderate-to-Severe Hidradenitis Suppurativa
NCT07727889Phase 2Active, not recruiting
- Sponsor
- Peking Union Medical College
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
A Phase 2 trial of upadacitinib in hidradenitis suppurativa (HS), sponsored by Peking Union Medical College. Started Jul 2026; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07727889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07727889.